5 ms·
Agreed! This specifically is for adjuvant osimertinib for EGFR+ Stage IB–IIIA completely resected NSCLC. The headline here is really strong -- and the actual a
by semenko 3y ago
Agreed! This specifically is for adjuvant osimertinib for EGFR+ Stage IB–IIIA completely resected NSCLC.
The headline here is really strong -- and the actual abstract is much more sober: "5-year OS rate was 88% with osimertinib vs 78% with placebo" [Full abstract is here: https://meetings.asco.org/abstracts-presentations/219805 https://meetings.asco.org/abstracts-presentations/219805 ]
P.S. Hi Chris! (I think I picked up a summer student from you last week!)
- haldujai 3y agoVery sober given the costs and %age of patients who didn’t receive adjuvant chemo in the initial trial. Interested to see their detailed results but I’m mildly suspicious this will be AstraZeneca PR buffing underwhelming results.